{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47","upperLimit":"76.9","value":"63.5"},{"comment":"Here, 'NA' refers that the upper limit of 95% confidence interval was not estimable due to a small number of participants with events.","groupId":"OG001","lowerLimit":"64.2","upperLimit":"NA","value":"81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"description":"Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 capsules of ibrutinib-matching Placebo administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a complete response (CR) or partial response (PR) continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment A up to 100.1 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment A discontinued placebo treatment.","id":"OG000","title":"Placebo + Bendamustine and Rituximab (BR) (Treatment A)"},{"description":"Participants received ibrutinib capsules 560 mg (4\\*140 mg capsule) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 mg/m\\^2 IV infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a CR or PR continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment B up to 117.2 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment B continued treatment with ibrutinib at the discretion of the investigator.","id":"OG001","title":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all randomized participants and classified according to the assigned treatment group, regardless of the actual treatment received. Participants who achieved a PR or better were included in the analysis of duration of response.","reportingStatus":"POSTED","timeFrame":"Up to 97 months","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}